Skip to main content
Premium Trial:

Request an Annual Quote

Nanopore Sequencing Startup Nabsys Closes $4M Equity Round


Nabsys said today that it has closed a $4 million equity round, led by Point Judith Capital. The Slater Technology Fund and other previous investors also participated in the round.

The Providence, RI-based company said it will use the proceeds to further develop its nanopore-based DNA sequencing technology, which combines solid-state nanopores with sequencing-by-hybridization.

Originally, both approaches were independently pursued by researchers at Brown University, who founded two companies, Nabsys and GeneSpectrum. In late 2006, Nabsys acquired GeneSpectrum in an all-stock transaction (see In Sequence 1/9/2007).

The idea of the technology is to use electrically addressable nanoarrays to determine the position of probes hybridized to long fragments of DNA. By repeating the process with many probes from a library and comparing the hybridization patterns, the DNA sequence can be deduced.

Nabsys was founded in 2004 by Brown professors Xinsheng Sean Ling and Leon Cooper, and has exclusively licensed nanopore technology developed by Ling, a professor of physics.

In 2007, Nabsys won a two-year, $480,000 grant from the National Human Research Institute's Advanced Sequencing Technology program to develop its hybridization-assisted nanopore sequencing, or HANS, technology. Separately, Ling won a three-year, $820,000 grant under the same program that year to develop the technology.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.